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Background: This study aims to identify whether the bacterial protein, Integration Host Factor (IHF), is present within sputum solids collected
from cystic ﬁbrosis (CF) patients and thus might contribute to the structural stability of bioﬁlms within the lungs.
Methods: The presence of IHF in sputum was determined by immunohistochemistry. The role of IHF in stabilizing bioﬁlms within sputum was
tested in vitro wherein anti-IHF was used to attempt to dissolve sputum solids.
Results: Thirty-seven of 44 sputum samples (84%) were positive for anti-IHF staining. Treatment with anti-IHF or DNase of 6 representative
samples, dissolved sputum solids signiﬁcantly better than treatment with normal saline in vitro, and strong synergism was observed when these
agents were used in combination.
Conclusions: IHF was detected in the majority of sputum samples from patients with CF and in vitro treatment with anti-IHF induced dissolution of
sputum solids. These data support further investigation of IHF as a potential therapeutic target for patients with CF.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Bioﬁlms; Integration host factor; Airway clearance; Pseudomonas aeruginosa1. Introduction
Cystic fibrosis is a lethal genetic disorder that causes
significant morbidity and early mortality [2,3]. Based on the
most recent data in the Cystic Fibrosis Foundation (CFF)☆ Data from this manuscript were presented at North American Cystic
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http://dx.doi.org/10.1016/j.jcf.2012.10.011Patient Registry, the median predicted age of survival is
38 years of age [4] and lung disease contributes to nearly 85%
of observed mortality [5]. Lung pathogenesis results from
dehydration of the airway surface liquid and impaired mucociliary
clearance [6–9]. As a result, individuals with CF have difficulty
clearing pathogens from the lungs and experience chronic
pulmonary infections and inflammation [6,10,11]. This pathogen-
esis remains the major cause of significantly decreased life span in
CF patients [6,10,11].
One of the most clinically relevant bacteria chronically
present in the lungs of CF patients is the Gram-negative
opportunistic pathogen Pseudomonas aeruginosa [11–14]. A
major cause of the persistence of P. aeruginosa in patients with
CF, and thus the establishment of chronic infection and
progressive lung destruction, is that these bacteria form and
reside within highly recalcitrant biofilm structures [15–17].by Elsevier B.V. All rights reserved.
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polymeric substance (EPS) that acts as a barrier to both effectors
of the immune system and antimicrobial agents. Recent work has
highlighted extracellular DNA (eDNA) as a key component in
many pathogenic biofilms [18,19]. It was recently shown that
members of the DNABII family of proteins are critical for the
integrity of the EPS matrix of biofilms formed by the human
pathogen nontypeable Haemophilus influenzae (NTHI) which
contains eDNA [18]. Integration Host Factor (IHF) is one of the
members of this family of proteins, existing as a heterodimer of
homologous subunits that binds and compacts double-stranded
DNA [20]. We have shown previously that antiserum directed
against isolated E. coli IHF (anti-IHF), either used alone or
combined with other treatment modalities such as DNase or
traditional antibiotics, is highly effective in its ability to debulk
biofilms and render the bacteria within more susceptible to the
action of antibiotics, respectively [18].
Since IHF has been proven to be an important element of the
structure of biofilms formed by NTHI and multiple other
human pathogens, and because biofilms within the respiratory
tract of patients with CF make treatment significantly more
difficult, we were interested in determining if the IHF protein
might also be present within clinical specimens obtained from
CF specimens, thus providing evidence that IHF may prove to
be a reasonable target for the development of novel therapies
for patients with CF.
2. Materials and methods
Sputum samples were collected from 44 patients with CF
(ages 4–63 years) during a routine clinic visit and under an
approved IRB between December 2010 and May of 2012.
Inclusion criteria were all CF patients who were able to produce
a sputum sample. Exclusion criteria were CF patients who had
undergone a lung transplant. A portion of the sample was sent
to the Clinical Microbiology lab at Nationwide Children's
Hospital for routine culture.
The portion of the sample brought to the lab was further split,
and half was used to determine the effect of anti-IHF and/or
DNase on sputum solids while the remaining portion was
embedded in OCT compound (Fisher Scientific, Pittsburgh, PA),
snap frozen over liquid nitrogen and stored at −80 °C until
further analysis. Ten micron serial sections were cut using a
Microm rotary cryotome, adhered to glass slides (Mercedes
Medical, Sarasota, FL) and stored at −80 °C. Sections were then
immunostained to determine the relative presence of IHF within
biomasses (or solids) present in CF sputum. Briefly, slides were
air-dried, fixed in cold acetone, equilibrated in buffer (0.05 M
Tris–HCl, 0.15 M NaCl and 0.05% Tween 20, pH 7.4), and
blocked with image-iT FX signal enhancer (Molecular Probes,
Eugene, OR) and with Background Sniper (BioCare Medical,
Concord, CA). Sections were then incubated with a 1:200
dilution of polyclonal rabbit anti-IHF (E. coli) overnight at 4 °C,
in a humidified chamber. Slides were rinsed and incubated with
goat anti-rabbit IgG conjugated to AlexaFluor 594 (Invitrogen,
Eugene, OR) for 30 min at room temp, counterstained with DAPI
to detect eDNA and cover-slipped using ProLong Gold antifadereagent (Molecular Probes, Eugene, OR). Use of naive rabbit
serum in place of immune serum and use of secondary antibody
alone served as negative control preparations. Sections were
viewed with a Zeiss LSM 510Meta confocal system attached to a
Zeiss Axiovert 200 inverted microscope (Carl Zeiss Inc.,
Thornwood, NY).
For further in vitro analysis, equal volumes of sputum
recovered from six patients (50 μl aliquots) were added to each
of 4 wells in an 8-well chamber slide (Fisher Scientific,
Pittsburgh, PA). Normal saline was added to the negative
control well and either saline that contained a 1:10 dilution of
DNase (Dornase Alfa, Pulmozyme, San Francisco, CA), saline
that contained a 1:50 dilution of rabbit anti-IHF serum or saline
that contained both DNase (1:10) and rabbit anti-IHF serum
(1:50) were added to the wells. Chamber slides were incubated
at 37 °C for 6 h as time–lapse images were collected at 15 min
intervals to visually assess dissociation of sputum solids.
To quantify this dissociation, equal volumes of sputum
(50 μl) were added to each of 5 wells of a 24-well plate.
Normal saline was added to one well as a negative control. The
other wells received either naive serum (negative control),
DNase (1:10), anti-IHF (1:10), or a combination of DNase plus
anti-IHF (both 1:10) diluted in saline. Changes in the optical
density of the solution surrounding sputum solids was
monitored using an Infinite M200Pro kinetic plate reader
(Tecan, Durham, N.C.). Absorbance readings at 600 nm were
collected every 5 min for 1 h while incubating at 37 °C
including at t=0 and at the endpoint (t =60 min). A total of 6
sputum samples were assessed in this manner. For statistical
analysis of changes in OD values, three blinded evaluators were
asked to select 5 defined regions of each well which contained
only the solution surrounding sputum solids. Changes in OD
for each of these five defined areas at t=0 were compared to
those obtained at t=60 for each well, and a Mixed Model was
used to test for group effects. A p-value≤0.05 was considered
significant.
3. Results
3.1. Clinical characteristics
Patients enrolled in the study ranged in age from 4 to 63 years
of age. There were 21 females and 23 males (48% and 52%
respectively). FEV1 of the patients ranged from 29 to 115%. Of
the samples collected for this study, 10 samples were collected
from patients who were experiencing an exacerbation at the time
of their visit. These ten samples were not distinguishable from
other samples in regards to immunolabeling for the presence of
IHF, FEV1 values, microbiology culture results or other patient
demographics.
3.2. Microbiology of sputum samples collected
The microorganisms identified from the sputum samples
which underwent microbiologic analysis (39 total) are shown in
Table 1 wherein P. aeruginosa (PA) was the most prominent
microorganism cultured. Seventy-seven percent of the sputum
Table 1
Microorganisms isolated from CF sputum samples.
CF sputum culture results Number of patients %
Pseudomonas aeruginosa 30 77
Non-mucoid 11 28
Mucoid 10 26
Both 9 23
Staphylococcus aureus 26 67
MSSA 15 38
MRSA 11 28
Both 0 0
Stenotrophomonas 7 19
Serratia 1 3
Aspergillus 3 8
E. coli 1 3
Achromobacter 2 5
Candida 1 3
Non-candidal yeast 1 3
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were also very prevalent within the samples collected from this
patient pool. Methicillin sensitive Staphylococcus aureus
(MSSA) and methicillin resistant S. aureus (MRSA) were
cultured from 38% and 28% of all samples, respectively. Of the
sputum samples collected, 73% were culture-positive for more
than one microorganism (Table 2), an observation which
indicated that CF infected lungs are populated by multiple
organisms, any of which may play a role in the pathogenesis of
this disease.
Two strain variants of P. aeruginosa, mucoidal and non-
mucoidal, have been implicated in CF lung infections with
the mucoidal variants being associated with more severe
cases [12,16,21]. In our study, we identified both variants, and
in some cases both types were present within the same sample.
Mucoidal Pseudomonas alone was observed in 26% (10/39) of
the sputum samples, while non-mucoidal Pseudomonas was
identified as the sole Pseudomonas variant in 28% (11/39) of the
samples. Additionally, 23% (9/39) of the samples had both
variants identified.
3.3. DNABII proteins were located at the vertices of bent and
crossed strands of eDNA contained within sputum samples
recovered from CF patients
To determine whether members of the DNABII family of
DNA binding proteins were in sputum samples recovered from
patients with CF, we examined whether rabbit polyclonal
antiserum directed against purified E. coli IHF (henceforth
referred to as ‘anti-IHF’) would label frozen sections of sputum
samples. We have previously found that while anti-IHF has
significant avidity for virtually all IHF and HU proteins across
genera, it is nonetheless highly specific for the DNABII family
of proteins [18] (data not shown). Overall, we found that
anti-IHF cross-reacting species were detected in 37 of 44 (84%)
of CF sputum samples analyzed here, regardless of which
bacterial species were present in the sample.
In terms of the spatial arrangement of IHF present within
these sputum samples, in Fig. 1, eDNA within the sputumsample can be seen as white strands, appearing in the form of an
interwoven lattice or mesh. We found positive immunolabeling
with anti-IHF antibody at virtually every visualized vertex of
eDNA observed within the sample, as shown by punctate
fluorescence signals (red) positioned wherever strands of
eDNA crossed one another. Use of naive rabbit serum in
combination with Alexa-Fluor conjugated goat-anti rabbit IgG,
or of Alexa Fluor conjugated goat anti-rabbit IgG alone, did not
result in this characteristic labeling of vertices (data not shown).
Based on these observations, strands of eDNA present in the
sputum of patients with CF were noted to be in association with
at least one extracellular DNABII protein. This observation was
identical to what we have observed in biofilms formed by
NTHI both in vitro and in vivo [18] wherein the presence of a
protein that was highly immunoreactive with antiserum
directed against isolated E. coli IHF was present at each
observed vertex of crossed strands of the abundant eDNA
contained within the biofilm. These data suggest a potential
common theme for biofilms formed in vivo within the
mammalian airway (and perhaps other organ systems as well)
regardless of the specific microbe involved or disease induced.
3.4. CF patient sputum was destabilized by treatment with
anti-IHF which also further enhanced treatment with DNase
Based on our previous work to date, and the considerable
strategic presence of IHF at vertices of crossed strands of the
eDNA lattice present within CF sputum samples as observed
here, collectively these data suggested that a DNABII family
member was involved in the formation and perhaps maintenance
of the structural integrity of this abundant eDNA-containing
lattice. We have previously shown the ability of anti-IHF to
disrupt the EPS of biofilms formed by numerous human
pathogens in vitro [18]. To determine if exposure to anti-IHF
might similarly result in a loss of structural integrity of the biofilm
matrix contained within CF sputum samples, we treated equal
volumes of 6 representative sputum samples ex vivo with either
saline, naive rabbit serum (negative control), anti-IHF, DNase or
with a combination of DNase plus anti-IHF. Furthermore, we
collected images of the samples at both t=0 and at t=60 min, and
observed a reduction of the visible sputum mass from all
treatment groups compared to the control groups (Fig. 2).
However, there was greater observed dissolution of the sputum
sample when incubated with the combination of anti-IHF and
DNase (Fig. 2, last column). These results suggested a loss of
structural integrity of the sputum sample as mediated by
incubation with anti-IHF that was equal to or greater than when
incubated with a current common treatment modality (DNase).
However, the dissolution of the sputum sample when incubated
with the combination of anti-IHF plus DNase was notable and
suggested the potential for synergistic use of these agents in the
treatment of patients with CF.
During the conduct of our in vitro dissolution assays, we
made the observation that as the sputum sample was disrupted
and the material that made up the sample was dispersed by
treatment, there was a discernable increase in the turbidity of
the incubation solution. In an effort to quantify this noted
Fig. 1. Representative image of immunohistochemical labeling for IHF (see
punctate area of red fluorescent labeling in image and as indicated by arrows in
inset) in OCT-embedded CF sputum samples. 10 μm section. Note: both
Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus
(MRSA) were cultured from this sample.
387J.E. Gustave et al. / Journal of Cystic Fibrosis 12 (2013) 384–389increase in turbidity of the surrounding solution as the central
semi-solid sputum mass was disrupted or dissolved, we
measured the optical density of the samples using a kinetic
plate reader which measured the absorbance at multiple points
per well. We found that in 83% (5/6) of the samples measured
in this manner after ~25 min incubation, there was a notable
increase in the optical density in the treatment wells compared
to their respective absorbance readings at t=0. OD readings
of treated wells increased further over time, but maximized,
reaching a plateau at ~1 h of incubation (data not shown). The
resulting mean absorbance readings obtained after 60 min of
incubation with either saline, anti-IHF, DNase or a combination
of anti-IHF plus DNase were graphed to demonstrate the
relative dissolution of sputum solids upon treatment. An
increase in turbidity was noted for samples treated with either
anti-IHF, DNase or a combination of these two agents,
compared to saline. This increase in turbidity was statistically
significant at 60 min of incubation (p≤0.05) for samples
treated with either anti-IHF or DNAse (Fig. 3), however
combined treatment with both agents resulted in even greater
increase in turbidity when compared to saline (p=0.0005).
4. Discussion
It is well known that a high concentration of eDNA in the
sputum of CF patients increases mucus viscosity and reduces
mucociliary clearance [7,22,23]. Chronic airway obstruction is
associated with impaired clearance of these highly viscoelastic
secretions [7,24,25]. Therefore, improving clearance of airway
secretions by decreasing the high viscoelasticity of the sputum
would have a significant beneficial clinical effect. Mucolytic
agents, such as N-acetylcysteine, which are directed against
mucus glycoproteins, have been associated with both irritation
of the airways and induction of bronchospasm with no
consistent beneficial effects [22,26]. Due to these drawbacks,
these mucolytic agents are not routinely used in the treatment of
CF. Instead, it has been found that there are more clinical
benefits using agents such as DNase and hypertonic saline for
daily airway clearance. Administration of hypertonic saline, an
osmotic agent which may improve airway hydration, or DNase,
which breaks down DNA and thereby also decreases mucus
viscosity [7,22,27], have shown beneficial effects. Their utility is
not however without questions, as there have been negativeTable 2
Number of microorganisms isolated from CF sputum samples (for those cultured).
CF sputum culture
positive for:
Number of
patients
% Most common bacterial
combinations
1 organism 10 28 MPA
2 organisms 14 38 PA/MSSA
3 organisms 10 27 PA/MPA/MSSA
or
PA/MPA/MRSA
N3 organisms 3 8 PA/MPA/MRSA/Aspergillus
PA/MPA/MSSA/Stenotrophomonas
MPA/MSSA/Aspergillus/
Stenotrophomonaseffects associated with use of hypertonic saline, such as decreased
lung function, bronchospasm and increased cough in some
patients [24]. DNase has also had anecdotal variable clinical
success, although it is generally tolerated well [22,24,27]. There
is certainly a need for additional airway clearance therapies which
may either be used alone, or perhaps in combination with
established modalities.
The source of the eDNA in sputum samples, as well as within
biofilms formed during disease, is derived from both the host as
well as the pathogens involved. However anti-IHF, as used here,
mediates its effect through action on eDNA whose origin is
bacterial, as BLAST searches of the human genome to date fail to
show significant amino acid sequence identity between the
DNABII proteins and any human protein. Microbes incorporate
bacterial DNA (and associated proteins such as the DNABII
proteins) into the EPS that surrounds and protects them when
resident within a biofilm [18,19]. The presence of an abundant
amount of eDNA within the lungs of CF patients and the effect
that this matrix component has both onmucus viscosity as well as
the stability of the biofilm matrix provides additional strong
support to the role of eDNA in the symptomology and chronicity
of CF. We have shown that a member(s) of the DNABII family
that cross reacts with anti-IHF plays an important role in the
structural integrity of the biofilm matrix formed by numerous
bacterial species by stabilizing the eDNA within the matrix [18].
In the present study, we examined whether any members of the
DNABII family were present in association with eDNA within
sputum of patients with CF.
Fig. 2. Representative images taken before and after 1 h incubation with either saline, anti-IHF (1:10), DNase (1:10), or a combination of anti-IHF and DNase
demonstrating the disruption of the sputum sample and increase in turbidity of the incubation solution.
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cultures were obtained in 39 of those and supported evidence
which shows that CF is truly a polymicrobial disease; 72% (28/39)
of the samples examined herein contained more than one
microorganism. P. aeruginosa was cultured most often in the
samples, however we were able to identify a total of 6 bacterial
species along with fungal pathogens. By immunohistochemical
analysis, an anti-IHF cross-reacting species was detected in 84% of
samples regardless of which bacterial agents were cultured. This
immunolabeling showed the presence of anti-IHF crossreacting
proteins positioned at the vertices of crossed strands of abundant
eDNA present within the sputum samples. Thus, at least one or
both known DNABII family members were likely critical
components in the maintenance of the structural integrity of
biofilms formed in the lungs of CF patients by P. aeruginosa, as
well as perhaps other pathogens. There were no detectable
differences in any patient characteristics between those that
generated sputum samples which yielded positive labeling for
IHF and those that yielded negative labeling results based on any of
the outcome measures used herein.Fig. 3. Mean absorbance readings of solution surrounding sputum solids as
obtained after incubation of six divided CF sputum samples for 1 h with either
saline, anti-IHF (1:10), DNase (1:10) or a combination of these latter two
agents. * denotes significant difference (p≤0.05) compared to saline, whereas
** denotes significance at p≤0.001.This observation suggested that DNABII family members
could be viable targets for either immune-mediated clearance or
perhaps that mediated by novel therapeutic agents, or a
combination of agents. Recently, we have demonstrated the
ability of antibodies directed against IHF to debulk biofilms
formed by numerous bacterial species in an in vitro assay [18].
Furthermore, we showed that when we immunized animals
with native IHF after they had already developed robust
biofilms in the middle ear following direct challenge of that
anatomical space with NTHI, the antibodies induced were able
to destabilize and debulk these pre-existing biofilms, thus
mediating more rapid resolution of experimental otitis media in
the chinchilla host that was statistically significant [18]. To
determine if we could similarly debulk or dissociate sputum
samples by incubation with anti-IHF, here we compared the
effect of treatment of CF sputum with anti-IHF in either the
absence or presence of DNase. To that end we demonstrated that
anti-IHF induced disruption of the sputum biomass to a degree
that was approximately equivalent to that mediated by treatment
with DNase alone. However, when these two treatments were
used in concert, we observed a strong synergistic effect wherein
almost complete dissolution of the sputum sample was mediated.
Moreover, we observed a measurable increase in the turbidity of
the incubation solution as early as ~25 min into incubation with
the combination of anti-IHF plus DNase and almost complete
disruption of the semi-solid sputum sample mass at 1 h. This
effect was highly statistically significant compared to treatment
with saline alone. Dissolution of sputum samples by either
anti-IHF or DNase was measured as an increase in turbidity in
83% of the samples tested in this manner. Whereas, due to small
sample size, sputum rheology was not measured in the present
study, this parameter of evaluation will be added to future work.
CF remains a life-shortening condition [2,3]. Disease manage-
ment and expanded newborn screening have led to a delay in
disease progression [28–30], however continued research is still
required to identify novel therapies that can alter the course of CF
lung disease. Directing the immune response against the DNABII
family of proteins which stabilize the eDNA present within
biomasses contained in CF sputum, and/or targeting this bacterial
protein for direct novel therapeutic interventions, may lead to
389J.E. Gustave et al. / Journal of Cystic Fibrosis 12 (2013) 384–389significantly improved mucociliary clearance and increased
susceptibility of resident bacteria to either host immune responses
or to other existing treatment modalities (e.g.DNase or antibiotics).Acknowledgements
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